12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Boehringer Ingelheim sales and marketing update

Boehringer launched Combivent Respimat ipratropium bromide/albuterol inhalation aerosol in the U.S. to treat chronic obstructive pulmonary disease (COPD) patients on an aerosol bronchodilator who...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >